Phathom Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary

Phathom Pharmaceuticals

06/03/2025 14:32

Phathom Pharmaceuticals Inc PHAT.OQ reported a quarterly adjusted loss of $1.05​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of $-1.39.  The mean expectation of eight analysts for the quarter was for a loss of $1.27 per share. Wall Street expected results to range from $-1.41 to $-1.17 per share.

Revenue rose 4,249.6% to $29.66 million from a year ago; analysts expected $24.91 million.

Phathom Pharmaceuticals Inc's reported EPS for the quarter was a loss of $1.05​.

The company reported a quarterly loss of $74.45 million.

Phathom Pharmaceuticals Inc shares had fallen by 25.1% this quarter.

FORECAST CHANGES

The mean earnings estimate of analysts had risen by about 0.3% in the last three months.​

In the last 30 days, two analysts negatively revised earnings estimates

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

The average consensus recommendation for the pharmaceuticals peer group is also "buy"

Wall Street's median 12-month price target for Phathom Pharmaceuticals Inc is $27.50

This summary was machine generated from LSEG data March 6 at 02:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Dec. 31 2024
-1.27
-1.05
Beat
Sep. 30 2024
-1.49
-1.32
Beat
Jun. 30 2024
-1.38
-1.56
Missed
Mar. 31 2024
-1.31
-1.42
Missed